Approxima SrlAnnounced the completion of a €7.3 million Series A round, jointly invested by ENEA Tech E BioMedical, Panakès Partners, and Simon Fiduciaria. The funds will be used for its core product.Preclinical validation, FIM clinical study, and early feasibility study in the United States."We have been supported since our establishmentApproxima Srl"And we have consistently adhered to this new and differentiated approach to provide clinicians and patients with entirely new treatment options."---Barbara Castellano, Partner at PanakèsPartners"This investment represents an important step forward in precision medicine innovation."Approxima SrlA unique solution for treating tricuspid regurgitation, a complex condition with significant limitations in current treatment options, has been developed. Our support for this groundbreaking technology underscores our commitment to advancing sophisticated and personalized solutions that not only improve patients' quality of life but also enhance the national healthcare system by promoting the development of cutting-edge medical devices. This investment is concrete evidence of how the synergy between research, technology, and capital can have a positive and lasting impact on the country's healthcare system.---Maria Cristina ENEA Tech E BioMedical General Manager"Guaranteed funds will accelerate patient accessApproxima Srl"A unique and transformative solution that directly addresses the root cause of the disease. This technology is strategically positioned within the emerging tricuspid valve therapies, making it a perfect fit for the portfolios of key players in the structural heart sector."---Umberto Pasquali Chairman of the Board"Over the past two years, our team has made significant technological advancements and provided robust preclinical evidence. We are thrilled to conclude this major financing round with the continued support of our current shareholders and new investors who share our vision. This milestone enables us to execute the next critical step of pilot clinical studies."
---Michal Jaworek, CEO and Co-founder of Approxima Srl"New treatment solutions are urgently needed to meet the growing clinical demand for tricuspid regurgitation. At Approxima Srl, we are developing an innovative technology that holds the promise of bridging this critical gap and improving patient outcomes. Secured funding will play a crucial role in accelerating patient access to this therapy."
---Paolo Denti Approxima SrlChief Medical Officer
APPROXIMAIs a new type of implantableHeartRoom RepeatPlasticDevice, consisting of a delivery system and an implant.
APPROXIMATheImplant BeltByConsisting of two anchors and an adjustable rope,TwoAnchorReleasePlaced on relatively opposite sides of the right ventricle,And throughAdjustable RopeConnection. The operator can proceed throughThe adjustable cord restores the dilated right ventricle to normal.
Comparison of APPROXIMA with Traditional TTVR and TTVr
Approxima SrlApproxima is an innovative medical device company incubated by Politecnico di Milano, established in 2020. Its mission is to develop a new type of implantable medical device for minimally invasive treatment of tricuspid valve and right heart failure. There are 4 million patients worldwide suffering from these diseases, which are currently considered inoperable.Approxima SrlAimed at meeting this emerging and yet unmet medical need.
